Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis
| Autor: | Christen Shoesmith, Ario Mirian, Sanjay Kalra, Lawrence Korngut, Scott Worley, Lorne Zinman, Kerri Schellenberg, Walter J. Hader, Ian Grant, Josh Lounsberry, Michel Melanson, Gary Linassi, Hannah Briemberg, Colleen O'Connell, Victoria Hodgkinson, Angela Genge, Rami Massie, Sean W. Taylor, Wendy Johnston, Timothy Benstead |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Neuromuscular disease 03 medical and health sciences 0302 clinical medicine Humans Medicine Registries 030212 general & internal medicine Motor Neuron Disease Amyotrophic lateral sclerosis Feeding tube Aged Riluzole business.industry Amyotrophic Lateral Sclerosis Muscle weakness General Medicine Middle Aged medicine.disease Dysphagia Clinical trial Neuroprotective Agents Neurology Respiratory failure Disease Progression Female Neurology (clinical) medicine.symptom business Excitatory Amino Acid Antagonists 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 45:652-659 |
| ISSN: | 2057-0155 0317-1671 |
| DOI: | 10.1017/cjn.2018.311 |
| Popis: | Background: Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease resulting in muscle weakness, dysarthria and dysphagia, and ultimately respiratory failure leading to death. Half of the ALS patients survive less than 3 years, and 80% of the patients survive less than 5 years. Riluzole is the only approved medication in Canada with randomized controlled clinical trial evidence to slow the progression of ALS, albeit only to a modest degree. The Canadian Neuromuscular Disease Registry (CNDR) collects data on over 140 different neuromuscular diseases including ALS across ten academic institutions and 28 clinics including ten multidisciplinary ALS clinics. Methods: In this study, CNDR registry data were analyzed to examine potential differences in ALS care among provinces in time to diagnosis, riluzole and feeding tube use. Results: Significant differences were found among provinces, in time to diagnosis from symptom onset, in the use of riluzole and in feeding tube use. Conclusions: Future investigations should be undertaken to identify factors contributing to such differences, and to propose potential interventions to address the provincial differences reported. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|